Tema GLP-1 Obesity & Cardiometabolic ETF (HRTS)
NASDAQ (NMS) NASDAQ (NMS) Primary 
New Year, New Strategy: Navigating Weight Loss ETFs
With the start of 2026, the annual focus on weight loss resolutions presents a timely opportunity for financial advisors to discuss the investment potential of GLP-1 agonists with their clients. This class of drugs has fundamentally altered the healthcare sector's growth projections.
Tap the Weight-Loss Drug Market With These ETFs
Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.
How to capitalize on the weight loss revolution with Tema Obesity & Cardiometabolic ETF (HRTS)
The weight loss revolution sparked by Novo Nordisk last year is attracting many investors towards the high risk biotech sector. An ETF like HRTS gives a lower risk exposure to the sector.
HRTS: Generating Alpha In Obesity Treatment
The Tema Obesity & Cardiometabolic ETF is a new actively managed fund focusing on the obesity treatment market. The investment strategy includes a mix of cash flow-positive companies, high-growth companies, and start-ups with promising technology. An interview with the PM increased my understanding and confidence in the portfolio construction and strategy.
HRTS: Exposure To GLP-1 Drug Developers Means Plenty Of Upside
By 2030, the weight loss drug market is estimated to reach a significant size, attracting many competitors due to the high prevalence of obesity-related comorbidities. The Tema Obesity & Cardiometabolic ETF offers exposure to leading biotech and pharma companies in the anti-obesity drugs market, focusing on GLP-1 medicines. HRTS outperformed the market since its inception, with a focus on mid-cap pharma businesses and a moderate risk profile, making it a favorable investment in the expanding cardiometabolic drugs market.
